MedTrace Logo

Text -Based Depression Screening Among Cancer Survivors

NCT06894849 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-08

No results posted yet for this study

Summary

Depression is common among cancer survivors, but current screening methods are not always effective. To help improve depression screening for cancer survivors, this study will conduct a pilot randomized controlled trial (RCT) with 60 participants. The goal is to evaluate whether a text message-based approach to depression screening is feasible, acceptable, and potentially more effective than the current standard of care.

Conditions

  • Cancer
  • Depression Secondary to Other Disease
  • Cancer Survivor

Interventions

BEHAVIORAL

Text-based depression screening

Starting 1 week prior to the scheduled clinic appointment, patients will receive a text message invitation from HCC to complete depression screening. Participants will be asked to click to continue to the screening PHQ-2. For text message screening cadence, reminder texts will be sent daily for 3 days. Those who screen positive (PHQ-2 \>/= 3) will complete the remainder of the items (i.e., PHQ-9).

BEHAVIORAL

Usual care (UC)

Usual care (UC) will consist of in-person assessment of depression using a validated brief screening tool (e.g., PHQ-2) synchronous with a clinical encounter with the outpatient oncology team. Although the person completing the screening (e.g., nurse, medical assistant) and other workflow may vary slightly across settings, the 2-items are generally presented orally to the patient during routine intake for a clinical encounter and entered into the EHR. Patients who screen positive will be asked to complete the full PHQ-9.

Sponsors & Collaborators

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Evan Graboyes, MD, MPH, FACS · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06894849 on ClinicalTrials.gov